High purity oritavancin and method of producing same
US-2019290723-A1 · Sep 26, 2019 · US
US8933012B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8933012-B2 |
| Application number | US-22444307-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 25, 2007 |
| Priority date | May 26, 2006 |
| Publication date | Jan 13, 2015 |
| Grant date | Jan 13, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a novel glycopeptide antibiotic derivative. These derivatives are represented by the formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R A is —X 1 —Ar 1 —X 2 —Y—X 3 —Ar 2 wherein X 1 , X 2 and X 3 are single bond; heteroatom-containing group selected from the group consisting of —N═, ═N—, —NR 1 — (R 1 is hydrogen or lower alkyl), —O—, —S—, —SO— and —SO 2 —, or a linkage thereof; or alkylene or alkenylene optionally substituted and optionally interrupted by one or more of said heteroatom-containing group; Y is —NR 2 CO—, —CONR 2 — (R 2 is hydrogen or lower alkyl), or a group of the formula (II) wherein R 3 is alkylene; Ar 1 and Ar 2 are a carbocycle or a heterocycle which is optionally substituted and may have an unsaturated bond; R B is —NHNR X R Y or —NR Z OR W wherein R X is hydrogen or lower alkyl; R Y is hydrogen, optionally substituted lower alkyl, C(═NH)NH 2 , CSNH 2 , COCONH 2 , CN, optionally substituted heterocyclic group, and optionally substituted carbamoyl; R Z is hydrogen or lower alkyl; R W is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted heterocyclic group, optionally substituted heterocyclic carbonyl or optionally substituted carbamoyl; R C is hydrogen or optionally substituted alkyl, wherein said alkyl may be interrupted by a heteroatom-containing group selected from N═, ═N—, —NR 1 — (R 1 is hydrogen or lower alkyl), —O—, —S—, —SO— and —SO 2 —; and R is optionally substituted alkyl.
Opening claim text (preview).
What is claimed is: 1. A compound of the formula: or a pharmaceutically acceptable salt thereof, wherein R A is —X 1 —Ar 1 —X 2 —Y—X 3 —Ar 2 wherein X 1 is C 1 -C 3 alkylene; X 2 is a single bond; X 3 is a single bond; Y is —NR 2 CO— or —CONR 2 -wherein R 2 is hydrogen or lower alkyl; and Ar 1 is a carbo…
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.